ClinicalTrials.gg
Status unknownNCT03610217PCTSUpdated Aug 6, 2018

Pragmatic Clinical Trials in Scleroderma

An interventional study of Interstitial lung disease induction algorithm and Pulmonary arterial hypertension algorithm in Scleroderma, Systemic and Sclerosis, Systemic, sponsored by University of West London. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-06.

Sponsored by University of West London · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Scleroderma, Systemic with a site in Canada — 12 open to participants now, 13 under way, 4 of them phase 3. Scleroderma, Systemic · Canada.

Planned enrollment
7th of 39
400 · median 115
Started
2018
with 3 others
No phase
11 of 44
1 open now
Registered
19th of 44
by date

Among the 44 studies in Scleroderma, Systemic with a site in Canada, this one is the 7th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2018, is one of 11 with no phase, and was the 19th registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

12 of the 44 studies in Scleroderma, Systemic with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Scleroderma, Systemic with a site in Canada, or all of them as a file.
02

Study summary

Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms.

With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them.

Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.

03

Conditions studied

  • Scleroderma, Systemic
  • Sclerosis, Systemic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient with an age >18 years meeting the 2013 SSc classification criteria managed at the Rheumatology division, St. Joseph's Healthcare London.
  • Patients who refuse to be randomized for treatments but wish to provide their data for the registry will also be included, after signing the form.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate or to sign an form.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Interstitial lung disease induction

    Other: Interstitial lung disease induction algorithm

  • Experimental
    Pulmonary arterial hypertension

    Other: Pulmonary arterial hypertension algorithm

  • Experimental
    Raynaud's phenomenon

    Other: Raynaud's phenomenon algorithm

  • Experimental
    Digital ulcers

    Other: Digital ulcer algorithm

  • Experimental
    Inflammatory arthritis

    Other: Inflammatory arthritis algorithm

  • Experimental
    Gastroesophageal reflux

    Other: Gastroesophageal reflux algorithm

  • Experimental
    Bacterial overgrowth

    Other: Bacterial overgrowth algorithm

  • Experimental
    Constipation

    Other: Constipation algorithm

  • Experimental
    Skin involvement

    Other: Skin involvement algorithm

  • Experimental
    Pain

    Other: Pain algorithm

Interventions

  • OtherInterstitial lung disease induction algorithm

    Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.

  • OtherPulmonary arterial hypertension algorithm

    Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)

  • OtherRaynaud's phenomenon algorithm

    Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly. Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.

  • OtherDigital ulcer algorithm

    Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option. Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option.

  • OtherInflammatory arthritis algorithm

    Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.

  • OtherGastroesophageal reflux algorithm

    Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.

  • OtherBacterial overgrowth algorithm

    Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.

  • OtherConstipation algorithm

    Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.

  • OtherSkin involvement algorithm

    Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. Patients with skin involvement and modified Rodnan skin score \>32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.

  • OtherPain algorithm

    Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.

06

What researchers measure

Primary outcomes

  1. Forced vital capacity %

    Variation of the forced vital capacity %

    Time frame: 1 year

  2. Bleeding

    Documentation of bleeding

    Time frame: 1 year

  3. Raynaud's phenomenon visual analog scale

    Raynaud's phenomenon visual analog scale variation ranging from 0 to 100 mm (0 no Raynaud's phenomenon, 100 very intense Raynaud's phenomenon)

    Time frame: 3 months

  4. Time to the healing of a digital ulcer

    Time to the healing of a digital ulcer

    Time frame: 1 year

  5. Time to the development of a new digital ulcer

    Time to the development of a new digital ulcer

    Time frame: 1 year

  6. Disease activity score 28

    Disease activity score 28 accounting for tender and swollen joints over 28 possible joints. Values \<2.6 remission, values \<3.2 low disease activity, values \>5.1 high disease activity

    Time frame: 3 months

  7. GERD-HRQL

    Variation of the Gastro-esophageal reflux disease-health related quality of life questionnaire, ranging from 0 (no symptoms) to 75 (worst symptoms)

    Time frame: 3 months

  8. Diarrhea visual analog scale

    Diarrhea visual analog scale variation ranging from 0 to 100 mm (0 no diarrhea, 100 very intense diarrhea)

    Time frame: 3 months

  9. Constipation visual analog scale

    constipation visual analog scale variation ranging from 0 to 100 mm (0 no constipation, 100 very intense constipation)

    Time frame: 3 months

  10. Modified Rodnan skin score

    Modified Rodnan skin score variation. Ranging from a total of 0 (no induration) to 51 (maximum induration)

    Time frame: 1 year

  11. Pain visual analog scale

    Pain visual analog scale variation, ranging from 0 to 100 mm (0 no pain, 100 very intense pain)

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Publications

  • Fernandez-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018 Nov;70(11):1820-1828. doi: 10.1002/art.40560. Epub 2018 Sep 17. PubMed 29781586 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2018; primary completion for Oct 2021, 36 months later.

Of 95 non-industry interventional studies with no phase under Scleroderma, Systemic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 36 months is above that.

Counting every sponsor, half of 101 studies reached it within 23 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2018
First posted
Aug 1, 2018
StartEst.
Oct 2018
Primary completionEst.
Oct 2021
CompletionEst.
Oct 2021
Last update
Aug 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03610217
Lead sponsor
University of West London
Collaborators
University of Western Ontario, Canada
Responsible party
Andreu Fernandez Codina (Principal investigator, University of Western Ontario, Canada) — Principal investigator
First posted
Aug 1, 2018
Start date
Oct 2018 (estimated)
Primary completion
Oct 2021 (estimated)
Completion
Oct 2021 (estimated)
Last update
Aug 6, 2018

Study contacts

Janet E Pope, MD, MPH, FRCPSC
Contact
Janet.Pope@sjhc.london.on.ca
15196466332
Andreu Fernandez-Codina, MD, MSc
Contact
doccodina@gmail.com
151964661023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion